Aardvark Therapeutics
AARD
49 hedge funds and large institutions have $126M invested in Aardvark Therapeutics in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 1 closing their positions.
1,400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 1
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
40% more funds holding
Funds holding: 35 → 49 (+14)
2.51% more ownership
Funds ownership: 41.09% → 43.61% (+2.5%)
4% more capital invested
Capital invested by funds: $121M → $126M (+$5.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.97M |
| 3 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$1.6M |
| 4 |
BlackRock
New York
|
+$1.17M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.8M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$288K |
| 3 |
Barclays
London,
United Kingdom
|
-$120K |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
-$39.2K |
| 5 |
Citigroup
New York
|
-$20.2K |
AARD Hedge Fund Activity: Q3 2025 in Review
49 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Aardvark Therapeutics (AARD) for Q3 2025, worth a combined $126M — up 4.3% from $121M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AARD positions and 1 closed out — a net gain of 14 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $3.6M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $10.8M sold.
- 49 institutional investors held Aardvark Therapeutics (AARD) as of Q3 2025, up from 35 in Q2 2025.
- Funds reported $126M of Aardvark Therapeutics stock for Q3 2025, up 4.3% quarter-over-quarter.
- 15 funds opened new Aardvark Therapeutics positions in Q3 2025 and 1 closed out, a net change of +14 holders.
- The largest Aardvark Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $3.6M added.
- The largest Aardvark Therapeutics seller in Q3 2025 was Cormorant Asset Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q3 2025.